Bruce Neal's Publications

About Bruce Neal's Publications

Executive Director, The George Institute for Global Health, Australia

  • Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 Diabetes

    JACC: Heart Failure Date published:

  • Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the CANVAS Program

    Diabetes, Obesity and Metabolism Date published:

  • Front-of-pack nutrition labelling to promote healthier diets: current practice and opportunities to strengthen regulation worldwide

    BMJ Global Health Date published:

  • The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS Program

    The Lancet Rheumatology Date published:

  • Canagliflozin Reduces Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Chronic Kidney Disease Regardless of Baseline HbA1c, Including Those With HbA1c < 7%: Results From the CREDENCE Trial

    Date published:

  • Do GLP-1 Receptor Agonists Care if You Have Heart Failure?

    Circulation Date published:

  • SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis

    The Lancet Diabetes & Endocrinology Date published:

  • Clinical characteristics, antihypertensive medication use and blood pressure control among patients with treatment-resistant hypertension

    Journal of Hypertension Date published:

  • Impact of dose and duration of dietary salt reduction on blood pressure levels: systematic review and meta-analysis of randomised trials

    Date published:

  • P1691Impact of dose and duration of dietary salt reduction on blood pressure levels: systematic review and meta-analysis of randomised trials

    European Heart Journal Date published:

  • Effects of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes in women versus men

    Diabetes, Obesity and Metabolism Date published:

  • Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS Program

    Journal of the American Society of Nephrology Date published:

  • The performance and potential of the Australasian Health Star Rating system: a four-year review using the RE-AIM framework

    Australian and New Zealand Journal of Public Health Date published:

  • Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups

    Circulation Date published:

  • Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program

    Diabetologia Date published:

  • Outcome Assessment by Central Adjudicators Versus Site Investigators in Stroke Trials

    Stroke Date published: